CN1316028C - Nα-脱乙酰化人胸腺素α1单体的表达载体、工程菌及其制备方法 - Google Patents
Nα-脱乙酰化人胸腺素α1单体的表达载体、工程菌及其制备方法 Download PDFInfo
- Publication number
- CN1316028C CN1316028C CNB031279376A CN03127937A CN1316028C CN 1316028 C CN1316028 C CN 1316028C CN B031279376 A CNB031279376 A CN B031279376A CN 03127937 A CN03127937 A CN 03127937A CN 1316028 C CN1316028 C CN 1316028C
- Authority
- CN
- China
- Prior art keywords
- thymosin alpha
- human thymosin
- alpha
- deacetylated
- engineering bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 29
- 239000000178 monomer Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 239000013604 expression vector Substances 0.000 title abstract description 9
- 108010046075 Thymosin Proteins 0.000 title description 22
- 102000007501 Thymosin Human genes 0.000 title description 21
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title description 21
- 230000000850 deacetylating effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 38
- 108010078233 Thymalfasin Proteins 0.000 claims abstract description 8
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims abstract description 8
- 229960004231 thymalfasin Drugs 0.000 claims abstract description 8
- 230000028327 secretion Effects 0.000 claims abstract description 7
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims abstract description 6
- 101500028961 Homo sapiens Thymosin alpha-1 Proteins 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 21
- 239000013612 plasmid Substances 0.000 claims description 14
- 238000000746 purification Methods 0.000 claims description 10
- 238000005336 cracking Methods 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 230000008521 reorganization Effects 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 239000012506 Sephacryl® Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 3
- 238000005571 anion exchange chromatography Methods 0.000 claims description 3
- 238000005277 cation exchange chromatography Methods 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 101900345593 Escherichia coli Alkaline phosphatase Proteins 0.000 claims description 2
- 101150062179 II gene Proteins 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000001641 gel filtration chromatography Methods 0.000 claims description 2
- 108010067006 heat stable toxin (E coli) Proteins 0.000 claims description 2
- 101150079876 mcrB gene Proteins 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 abstract description 23
- 230000004151 fermentation Effects 0.000 abstract description 23
- 230000008569 process Effects 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000003381 deacetylation reaction Methods 0.000 abstract 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 210000001541 thymus gland Anatomy 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108010077805 Bacterial Proteins Proteins 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000012407 engineering method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012925 reference material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940023064 escherichia coli Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940124872 Hepatitis B virus vaccine Drugs 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- -1 thymosin amino acid Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031279376A CN1316028C (zh) | 2003-04-25 | 2003-04-25 | Nα-脱乙酰化人胸腺素α1单体的表达载体、工程菌及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031279376A CN1316028C (zh) | 2003-04-25 | 2003-04-25 | Nα-脱乙酰化人胸腺素α1单体的表达载体、工程菌及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1539978A CN1539978A (zh) | 2004-10-27 |
CN1316028C true CN1316028C (zh) | 2007-05-16 |
Family
ID=34322090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031279376A Expired - Lifetime CN1316028C (zh) | 2003-04-25 | 2003-04-25 | Nα-脱乙酰化人胸腺素α1单体的表达载体、工程菌及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1316028C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104933217A (zh) * | 2014-03-18 | 2015-09-23 | 株式会社岛精机制作所 | 针织设计系统和针织设计方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0035454A2 (en) * | 1980-02-28 | 1981-09-09 | Genentech, Inc. | Desacetylthymosin alpha 1, its process of preparation and its use |
SU1707078A1 (ru) * | 1989-11-21 | 1992-01-23 | Институт биоорганической химии им.М.М.Шемякина | Рекомбинантна плазмидна ДНК рТНУЗ14, кодирующа полипептид со свойствами тимозина @ человека, рекомбинантна плазмидна ДНК рТНУ12 - промежуточный продукт дл ее конструировани и штамм бактерий ЕSснеRIснIа coLI - продуцент полипептида со свойствами тимозина @ человека |
CN1258747A (zh) * | 1998-12-30 | 2000-07-05 | 中国人民解放军第四军医大学 | 以大肠杆菌制备4串体胸腺素α1 |
CN1326947A (zh) * | 2000-06-01 | 2001-12-19 | 北京双鹭药业有限责任公司 | 人胸腺素α原基因突变体合成、表达及应用 |
-
2003
- 2003-04-25 CN CNB031279376A patent/CN1316028C/zh not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0035454A2 (en) * | 1980-02-28 | 1981-09-09 | Genentech, Inc. | Desacetylthymosin alpha 1, its process of preparation and its use |
SU1707078A1 (ru) * | 1989-11-21 | 1992-01-23 | Институт биоорганической химии им.М.М.Шемякина | Рекомбинантна плазмидна ДНК рТНУЗ14, кодирующа полипептид со свойствами тимозина @ человека, рекомбинантна плазмидна ДНК рТНУ12 - промежуточный продукт дл ее конструировани и штамм бактерий ЕSснеRIснIа coLI - продуцент полипептида со свойствами тимозина @ человека |
CN1258747A (zh) * | 1998-12-30 | 2000-07-05 | 中国人民解放军第四军医大学 | 以大肠杆菌制备4串体胸腺素α1 |
CN1326947A (zh) * | 2000-06-01 | 2001-12-19 | 北京双鹭药业有限责任公司 | 人胸腺素α原基因突变体合成、表达及应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104933217A (zh) * | 2014-03-18 | 2015-09-23 | 株式会社岛精机制作所 | 针织设计系统和针织设计方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1539978A (zh) | 2004-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4495282A (en) | Process for producing target cell lysis factor and uses therewith | |
CN1032315C (zh) | 在酵母中生产乙型肝炎病毒蛋白质的方法 | |
Blanchard et al. | Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. | |
CN101787080A (zh) | 一种抗甲型h1n1流感病毒特异性鸡卵黄抗体制备方法 | |
CN1316028C (zh) | Nα-脱乙酰化人胸腺素α1单体的表达载体、工程菌及其制备方法 | |
CN106350527A (zh) | 一种可在大肠杆菌可溶性高表达的白喉毒素突变体 | |
CN101376887B (zh) | 猪口蹄疫重组免疫复合肽的制备方法及应用 | |
CN102492714A (zh) | 一种重组中华田园犬α干扰素的制备方法 | |
JPH0587519B2 (zh) | ||
GB2121053A (en) | Production of interleukin and its analogous immune regulating factors | |
EP0158317B1 (en) | Method of preparing a biologic | |
CN1281623C (zh) | 抗病毒活性的人α干扰素衍生物 | |
JPH0365362B2 (zh) | ||
NO173144B (no) | Fremgangsmaate til fremstilling av interferongamma | |
CN100384998C (zh) | 重组鹅白细胞介素-2蛋白的制备方法及其用途 | |
CN1408863A (zh) | 一种人白细胞介素-10基因序列及含该基因序列的大肠杆菌 | |
CN104530212A (zh) | 一种免疫调节肽及其制备方法和应用 | |
CN1063343C (zh) | 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白 | |
CN101591397A (zh) | 长效胸腺素α1的重组表达及其用途 | |
CN1258747A (zh) | 以大肠杆菌制备4串体胸腺素α1 | |
CN102559818A (zh) | 一种诱导产生Ⅲ型干扰素-λ1的方法 | |
JPH0645550B2 (ja) | 抗癌剤 | |
CN1840682A (zh) | 用基因工程方法大量生产高活性的胸腺素a1 | |
CN101302252B (zh) | 一种胸腺素alphal(Tαl)类似物及生产工艺和医用途 | |
EP0308717B1 (en) | Method of treating viral encephalitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: YUNMENG DEBANG INDUSTRIAL CO., LTD. Free format text: FORMER OWNER: CHUANGJI TECH CO., LTD., HUBEI Effective date: 20101102 |
|
C56 | Change in the name or address of the patentee | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 432500 HUBEI CHUANGJI SCIENCE AND TECHNOLOGY CO., LTD., NO.20, MENGZE AVENUE, CHENGGUAN, YUNMENG COUNTY, HUBEI PROVINCE TO: 432500 MENGZE AVENUE, CHENGGUAN, YUNMENG COUNTY, XIAOGAN CITY, HUBEI PROVINCE |
|
CP01 | Change in the name or title of a patent holder |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: CHANGCHUN GENESCIENCE PHARMACEUTICALS Corp. Address before: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: CHANGCHUN GENESCIENCE PHARMACEUTICAL Co.,Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: JINSAI MEDICINE CO., LTD., CHANGCHUN Free format text: FORMER NAME: CHANGCHUN GENSCI PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: CHANGCHUN GENESCIENCE PHARMACEUTICAL Co.,Ltd. Address before: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: CHANGCHUN GENESCIENCE PHARMACEUTICALS Corp. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: CHANGCHUN GENESCIENCE PHARMACEUTICALS Corp. Address before: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: CHANGCHUN GENESCIENCE PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: CHANGCHUN GENESCIENCE PHARMACEUTICAL Co.,Ltd. Address before: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: CHANGCHUN GENESCIENCE PHARMACEUTICALS Corp. |
|
CP01 | Change in the name or title of a patent holder | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070516 |